OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

OraSure Technologies Inc (NASDAQ: OSUR) reported Q3 revenues of $53.92 million, +12% Y/Y, beating the consensus of $47.48 million. Excluding COVID-19 product-related sales, revenues grew by 37%, demonstrating strong growth.

OraSure Q3 Sales, Without COVID Related Products, Jump 37%; Guides FY21 Sales Below Consensus

OraSure Technologies' (OSUR) CEO Stephen Tang on Q3 2021 Results - Earnings Call Transcript

Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET

OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22

The FDA has amended OraSure Technologies Inc's (NASDAQ: OSUR) Emergency Use Authorization (EUA) for its InteliSwab COVID-19 rapid tests to only require one test for symptoms of COVID-19.  Related Link:   OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity.

FDA Authorizes OraSure's COVID-19 Rapid Tests For OTC Single-Use

BETHLEHEM, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the EUA for its InteliSwab™ COVID-19 rapid tests has been amended by the U.S. Food and Drug Administration (FDA) to only require one test for individuals with symptoms of COVID-19. Previously, the at-home test was authorized for over-the-counter use in people with or without symptoms when tested twice with at least 24 hours but not more than 36 hours between tests, which is called serial testing. Now, people with symptoms only need to test once; people without symptoms should still perform serial testing if they get a negative result on their first test.

U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for

BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November 3, 2021.

OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET

OraSure is an underfollowed name with strong growth potential selling simple to use COVID-19 rapid test kits, given another wave of virus spread is approaching during the winter. With over $3 in cash per share, a $5 tangible book value, and few liabilities, the company holds a unique balance sheet "margin of safety."

The Bottom Fishing Club: OraSure Technologies

OraSure Technologies Inc (NASDAQ: OSUR) has secured a $109 million contract from the U.S. Department of Defense to build additional manufacturing capacity in the U.S. for InteliSwab COVID-19 rapid tests. Related:   OraSure Secures $13.6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver.

OraSure Wins $109M Contract To Increase COVID-19 Test Manufacturing Capacity

Investors need to pay close attention to OraSure Technologies (OSUR) stock based on the movements in the options market lately.

Implied Volatility Surging for OraSure Technologies (OSUR) Stock Options

Agreement Ensures OraSure Will Have Sufficient Capacity to Meet Market Need for Rapid Antigen Tests and Ensure Future Preparedness Agreement Ensures OraSure Will Have Sufficient Capacity to Meet Market Need for Rapid Antigen Tests and Ensure Future Preparedness

OraSure Awarded $109 Million Contract from U.S. Department of Defense to Ramp Manufacturing of InteliSwab™ COVID-19 Rapid Test

BETHLEHEM, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), will provide up to $13.6 million in funding for the Company to obtain 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for OraSure's InteliSwab™ COVID-19 rapid test from the Food and Drug Administration (FDA).

OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

The Defense Logistics Agency has awarded OraSure Technologies Inc (NASDAQ: OSUR) a procurement contract for its InteliSwab COVID-19 Rapid Test for over-the-counter use. Related Link:   OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates.

OraSure Secures $205M Contract For OTC COVID-19 Tests

BETHLEHEM, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Defense Logistics Agency has awarded the Company a procurement contract for its InteliSwab™ COVID-19 Rapid Test for over-the-counter use, which the Defense Logistics Agency estimated to have a value of $205 million. Under the terms of the contract, OraSure will provide its InteliSwab™ COVID-19 Rapid Test to up to 25,000 sites throughout the United States and the tests will be funded by the U.S. federal government. The contract will run from October 2021 through September 2022.

OraSure Receives $205 Million Procurement Contract for InteliSwab™ from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Response

Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO

OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan

OraSure Technologies Inc (NASDAQ: OSUR) reported second-quarter revenues almost doubled to $57.6 million, slightly ahead of the consensus of $56.69 million. Excluding COVID-19 revenues, sales were up 122% Y/Y and 48% sequentially, which the firm attributed to the beginning of a return of its core business to pre-pandemic levels.

OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q2 2021 Results - Earnings Call Transcript

Shares of OraSure Technologies (NASDAQ:OSUR) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 87.50% over the past year to ($0.02), which missed the estimate of $0.04.

OraSure Technologies: Q2 Earnings Insights

OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business

OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

BETHLEHEM, Pa., July 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, August 3, 2021.

OraSure Technologies, Inc. to Hold 2021 Second Quarter Earnings Conference Call Tuesday, August 3, 2021, 5:00 p.m. ET

BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference. The conference will be simultaneously webcast over the Internet.

OraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference

Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status

OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing

OraSure Technologies Inc (NASDAQ: OSUR) has received FDA Emergency Use Authorization (EUA) for its COVID-19 rapid antigen tests, InteliSwab. These tests detect active COVID-19 infection; the agency has given the emergency nod for Over-the-Counter use.

OraSure's COVID-19 Rapid Antigen Tests Gets FDA Emergency Approval for OTC, Professional, Prescription Use

Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection

OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescription (OTC), Professional and Prescription Use

News for OraSure Technologies Stock (OSUR)